Difference between revisions of "Lamivudine (Epivir)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "analogue" to "analog") |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Antiretroviral; Lamivudine is a cytidine | + | Class/mechanism: Antiretroviral; Lamivudine is a cytidine analog and can inhibit both types (1 and 2) of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B. |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: N/A | <br>Extravasation: N/A | ||
Revision as of 13:51, 23 September 2023
General information
Class/mechanism: Antiretroviral; Lamivudine is a cytidine analog and can inhibit both types (1 and 2) of HIV reverse transcriptase and also the reverse transcriptase of hepatitis B.
Route: PO
Extravasation: N/A
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
No known antineoplastic properties. Used for prevention of HBV reactivation for HBV carriers.
Also known as
- Brand name: Epivir